Article ; Online: Immediate possible adverse event rates in infants treated with oral propranolol for infantile haemangiomas at an Australian urban tertiary hospital between 2016 and 2019.
The Australasian journal of dermatology
2022 Volume 63, Issue 4, Page(s) 473–478
Abstract: Background/objectives: Infantile haemangiomas (IH) are common benign tumours of childhood. The current guideline recommended treatment is oral propranolol, the use of which for IH is relatively recent and there are no safety audits in Australian ... ...
Abstract | Background/objectives: Infantile haemangiomas (IH) are common benign tumours of childhood. The current guideline recommended treatment is oral propranolol, the use of which for IH is relatively recent and there are no safety audits in Australian children published. As a result, it is a primarily inpatient initiated treatment. The aim of this study was to examine the short-term complication rates in infants treated with oral propranolol for IH. Methods: Retrospective case note review of IH patients initiated on oral propranolol admitted to the day-unit of tertiary metropolitan hospital in an Australia capital city, from January 2016 to December 2019. Results: Overall, 72 children were included in the study. Mean age at time of admission was 3.8 ± 2 months. Eight patients (11.1%) experienced complications during their initiation admission. Pulmonary complications (oxygen desaturation, wheeze, increased respiratory rate) was the most common type. No children required high-dependency or intensive care unit admission. The children who experienced complications had a mean age of 2.4 ± 1.2 months; t-test of equality of means found a relationship between propranolol-associated complication rate and age (p = 0.007). All other patient or admission characteristics were not associated with complication events (all p > 0.05). Conclusions: Propranolol is a safe, effective and well-tolerated treatment in Australian children with IH. This study demonstrates younger infants will most likely benefit from inpatient initiation. More research needs to be done to characterise the risk profile of propranolol initiation for IH. |
---|---|
MeSH term(s) | Infant ; Humans ; Propranolol/adverse effects ; Hemangioma/drug therapy ; Retrospective Studies ; Tertiary Care Centers ; Adrenergic beta-Antagonists ; Skin Neoplasms/drug therapy ; Australia ; Hemangioma, Capillary/complications ; Hospitals, Urban ; Treatment Outcome ; Administration, Oral |
Chemical Substances | Propranolol (9Y8NXQ24VQ) ; Adrenergic beta-Antagonists |
Language | English |
Publishing date | 2022-08-08 |
Publishing country | Australia |
Document type | Journal Article |
ZDB-ID | 138052-7 |
ISSN | 1440-0960 ; 0004-8380 |
ISSN (online) | 1440-0960 |
ISSN | 0004-8380 |
DOI | 10.1111/ajd.13906 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 236: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.